{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-003889","form_type":"8-K","ticker":"KALA","cik":"0001479419","company_name":"KALA BIO, Inc.","filed_at":"2024-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.294162+00:00","generated_at":"2026-06-04T07:48:35.514192+00:00","sec_items":["1.01","5.03","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"KALA BIO raises $8.6M in private placement of Series G convertible preferred stock","bullets":["Gross proceeds of $8.6 million from sale of 10,901 Series G Preferred shares at $788.90 each.","Each Series G share initially convertible into 100 common shares, subject to 9.99% beneficial ownership limitation.","Closing expected on March 26, 2024; offering exempt under Section 4(a)(2) and Regulation D.","Company filed Certificate of Designations with Delaware establishing Series G Preferred Stock terms."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-003889","json":"https://secwatch.observer/filing/0001558370-24-003889.json","markdown":"https://secwatch.observer/filing/0001558370-24-003889.md","text":"https://secwatch.observer/filing/0001558370-24-003889.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479419/000155837024003889/0001558370-24-003889-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479419/000155837024003889/kala-20240325x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T07:48:35.514192+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9b4ab7ef59fe29f06821bfe3ae00be9129941d85","claim":"KALA BIO, Inc.: Filed Certificate of Designations for Series G Convertible Non-Redeemable Preferred Stock (effective 2024-03-25).","evidence_excerpt":"On March 25, 2024 (the “Filing Date”), the Company filed a Certificate of Designations, Preferences and Rights of Series G Convertible Non-Redeemable Preferred Stock (the “Certificate of Designations”) with the Secretary of State of the State of Delaware with respect to the Series G Preferred Stock.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1479419/000155837024003889/0001558370-24-003889-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-03-25"}],"fact_type":"governance_change"},{"claim_id":"ae4aece510d6d4cceb6147890fea867f422b5713","claim":"KALA BIO, Inc. entered into Securities Purchase Agreement with certain institutional investors named therein valued at aggregate gross proceeds of approximately $8.6 million (effective 2024-03-25).","evidence_excerpt":"On March 25, 2024, KALA BIO, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain institutional investors named therein (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a private placement priced at-the-market under Nasdaq rules, shares (the “Preferred Shares”) of Series G Convertible Non-Redeemable Preferred Stock, par value $0.001 per share, of the Company (the “Series G Preferred Stock”), for aggregate gross proceeds of approximately $8.6 million (the “Private Placement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1479419/000155837024003889/0001558370-24-003889-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors named therein"},{"label":"Value","value":"aggregate gross proceeds of approximately $8.6 million"},{"label":"Effective","value":"2024-03-25"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}